Anti-Tumour TreatmentOsteosarcoma treatment – Where do we stand? A state of the art review
Introduction
Following the implementation of chemotherapy in the 1970s, the treatment of high-grade malignant osteosarcoma (OS) has made important progress. However, survival rates continue to be unsatisfactory in the metastatic and relapse setting. Understanding OS biology still remains a complex challenge. An unknown etiology, high genetic instability of OS cells, a wide histological heterogeneity, lack of biomarkers, high local aggressiveness, and a rapid metastasizing potential create pivotal questions to be answered. The purpose of this paper is to outline recent developments in the field of osteosarcoma therapies.
Section snippets
Search strategy and selection criteria
We searched PubMed for the past 12 years (January 2001–October 2013) with the terms “osteosarcoma” and “treatment”. The abstracts were screened to identify those research studies and review articles we judged relevant to our objectives. This procedure identified 166 potentially eligible publications which were studied in detail. A particular relevance was given to reports on systemic therapy. References from these articles were also obtained, and review articles are cited to provide readers with
Background
Osteosarcoma (OS) defines neoplasms that share the histological finding of osteoid production in association with malignant mesenchymal cells. These tumors are generally locally aggressive and tend to produce early systemic metastases [1]. A distinction is generally drawn between different histologic types of OS (conventional, teleangiectatic, parosteal, periosteal, low-grade central, small cell, not otherwise specified). The conventional type is the most common, and has been subdivided based
Pediatric Oncology Group (POG) and Children’s Oncology Group (COG)
The advantages of presurgical chemotherapy include early administration of systemic chemotherapy, shrinkage of primary tumor, and pathologic identification of risk groups. The theoretic disadvantage is that it exposes a large tumor burden to marginally effective chemotherapy [50]. A randomized study of the Pediatric Oncology Group (POG 8651) compared immediate surgery with delayed surgery after induction of chemotherapy. Outcome was not significantly different between both arms, which means
European and American Osteosarcoma Study Group (EURAMOS)
EURAMOS was founded in 2001. Four trial groups (COSS, COG, EOI, and SSG) joined together to undertake the first clinical trial of EURAMOS, EURAMOS-1, which opened in 2005. The study design includes a standard preoperative therapy using MAP. Following surgery, patients were stratified according to histological response. Patients classified as good responders (⩾90% necrosis) were randomized to continue MAP or to receive MAP followed by maintenance pegylated interferon alpha (IFN-α), while poor
Conflict of interest
None declared.
References (96)
- et al.
Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide
Ann Oncol
(2003) - et al.
Clinico-histologic parameters of osteosarcoma patients with late relapse
Eur J Cancer
(2006) - et al.
The influence of tumor- and treatment-related factors on the development of local recurrence in osteosarcoma after adequate surgery. An analysis of 1355 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols
Ann Oncol
(2011) - et al.
Radiotherapy for local control of osteosarcoma
Int J Radiat Oncol Biol Phys
(2005) - et al.
Neoadjuvant chemotherapy and local radiotherapy for high-grade osteosarcoma of the extremities
Mayo Clin Proc
(2003) - et al.
153Samarium-EDTMP administration followed by hematopoietic stem cell support for bone metastases in osteosarcoma patients
Ann Oncol
(2012) - et al.
Primary bone osteosarcoma in the pediatric age: state of the art
Cancer Treat Rev
(2006) - et al.
Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects
Lancet Oncol
(2010) - et al.
Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand?
Eur J Cancer
(2011) - et al.
Long-term results of the co-operative German–Austrian–Swiss osteosarcoma study group’s protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs
Ann Oncol
(1998)
European Osteosarcoma Intergroup. Survival after recurrent osteosarcoma: data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials
Eur J Cancer
SSGVIII study: prognostic factors for outcome and role of replacement salvage chemotherapy for poor histologic responders
Eur J Cancer
Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli’s 4th protocol
Eur J Cancer
Survival in high-grade osteosarcoma: improvement over 21 years at a single institution
Ann Oncol
SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients
Eur J Cancer
Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European osteosarcoma intergroup
Lancet
Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Ontergroup randomised controlled trials
Ann Oncol
Prognostic factors and outcomes for osteosarcoma: an international collaboration
Eur J Cancer
Osteosarcoma over the age of forty
Eur J Cancer
Update on targets and novel treatment options for high-grade osteosarcoma and chondrosarcoma
Hematol Oncol Clin North Am
A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group Study
Ann Oncol
Osteosarcoma multidisciplinary approach to the management from the pathologist’s perspective
Cancer Treat Res
Current concepts on the molecular biology of osteosarcoma
Cancer Treat Res
Casali PG; ESMO guidelines working group. Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up
Ann Oncol
Genetic alterations in primary osteosarcoma from 54 children and adolescents by targeted allelotyping
Br J Cancer
The epidemiology of osteosarcoma
Cancer Treat Res
Osteosarcoma: a review of diagnosis, management, and treatment strategies
Clin Adv Hematol Oncol
COSS study group. Osteosarcoma in very young children: experience of the Cooperative Osteosarcoma Study Group
Cancer
Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1702 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols
J Clin Oncol
Osteosarcoma: the COSS experience
Cancer Treat Res
Osteosarcoma of the spine: experience of the Cooperative Osteosarcoma Study Group
Cancer
A review of clinical and molecular prognostic factors in osteosarcoma
J Cancer Res Clin Oncol
Osteosarcoma: improvement in survival limited to high-grade patients only
J Cancer Res Clin Oncol
Osteosarcoma of the pelvis: experience of the Cooperative Osteosarcoma Study Group
J Clin Oncol
Osteosarcoma treatment: state of the art
Cancer Metastasis Rev
Osteosarcoma of the mobile spine
Spine (Phila Pa 1976)
Poor survival for osteosarcoma of the pelvis: a report from the children’s oncology group
Clin Orthop Relat Res
Therapy for osteosarcoma: where do we go from here?
Paediatr Drugs
Bone metastases in osteosarcoma patients treated with neoadjuvant or adjuvant chemotherapy: the Rizzoli experience in 52 patients
Acta Orthop
Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols
J Clin Oncol
Osteosarcoma lung metastases detection and principles of multimodal therapy
Cancer Treat Res
Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS)
J Clin Oncol
Palliative therapy for osteosarcoma
Expert Rev Anticancer Ther
High grade osteosarcoma of the extremities with lung metastases at presentation: treatment with neoadjuvant chemotherapy and simultaneous resection of primary and metastatic lesions
J Surg Oncol
Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival
J Clin Oncol
Solitary skeletal osteosarcoma recurrence. Findings from the Cooperative Osteosarcoma Study Group
Pediatr Blood Cancer
Cannon SR; surgical subcommitte of the European Osteosarcoma Intergroup. Surgical outcomes in osteosarcoma
J Bone Joint Surg Br
The incidence and prognosis of osteosarcoma skip metastases
Clin Orthop Relat Res
Cited by (1033)
Two-dimensional layered double hydroxides for biomedical applications: From nano-systems to surface- and body-systems
2024, Progress in Materials ScienceA bibliometric and visualized analysis of nanoparticles in musculoskeletal diseases (from 2013 to 2023)
2024, Computers in Biology and MedicineHigh-grade osteosarcoma arising in DCIA flap reconstruction after a prior resection of maxillar cemento-ossifying fibroma: A case report
2024, Journal of Stomatology, Oral and Maxillofacial SurgeryBifunctional bone substitute materials for bone defect treatment after bone tumor resection
2023, Materials Today Bio
- 1
Recipient of a non-restricted grant by Takeda GmbH.